Status
Conditions
Treatments
About
Retrospective review of old patients
Prospective case-control study: RNA sequencing & miRNA microarray
naive esophageal cancer patients who have a plan to receive concomitant chemo-radiotherapy
***Analysis of mRNA sequencing / miRNA sequencing**** first analysis of RNA sequencing: bioinformatician second analysis of RNA sequencing: principle investigator
Experimental set for qPCR (esophageal tissue) study group
TMA for screened exon gene
validation set for qPCR (esophageal tissue)
follow-up of circulating miRNA in blood (baseline blood & post-CCRT blood 3M, 6M, 12M)
Prediction model for CCRT response in esophageal Cancer based on clinical and molecular factors
Validate the prediction model.
Full description
Retrospective review of old patients
Study Group
Prospective case-control study: RNA sequencing & miRNA microarray
study group
non-responder (N=14)
Complete Remission (N=14)
For considering the drop rate, 2-fold screening
***Analysis of mRNA sequencing / miRNA sequencing**** first analysis of RNA sequencing: bioinformatician second analysis of RNA sequencing: principle investigator
non-responder (N=40)
complete remission (N=40)
TMA for screened exon gene
validation set for qPCR (esophageal tissue) new esophageal cancer set
non-responder (N=30)
complete remission (N=30)
follow-up of circulating miRNA in blood (baseline blood & post-CCRT blood 3M, 6M, 12M)
Prediction model for CCRT response in esophageal Cancer based on clinical and molecular factors
Test several combination models
gene + gene combination,
gene + clinical information combination,
gene + gene + clinical information combination
Validate the prediction model.
primary organoid culture and prediction of chemoradiotherapy response
Enrollment
Sex
Ages
Volunteers
Inclusion criteria
Exclusion criteria
140 participants in 2 patient groups
Loading...
Central trial contact
Su Youn Y Nam, MD, PhD
Data sourced from clinicaltrials.gov
Clinical trials
Research sites
Resources
Legal